{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:14:06Z","timestamp":1791213246649,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,5,15]]},"DOI":"10.1097\/tp.0b013e3181a27683","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T21:12:27Z","timestamp":1242940347000},"page":"1394-1401","source":"Crossref","is-referenced-by-count":26,"title":["Reconstitution of Peripheral Allospecific CD19+ B-Cell Subsets After B-Lymphocyte Depletion Therapy in Renal Transplant Patients"],"prefix":"10.1097","volume":"87","author":[{"given":"Dessislava","family":"Kopchaliiska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea A.","family":"Zachary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary S.","family":"Leffell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20210129","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1034\/j.1600-6143.2003.00072.x","article-title":"Antibody-mediated rejection criteria\u2014An addition to the Banff 97 classification of renal allograft rejection.","volume":"3","author":"Racusen","year":"2003","journal-title":"Am J Transplant"},{"key":"R2-21-20210129","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/01.TP.0000129256.84027.D6","article-title":"Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols.","volume":"78","author":"Montgomery","year":"2004","journal-title":"Transplantation"},{"key":"R3-21-20210129","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1600-6143.2004.00500.x","article-title":"National conference to assess antibody-mediated rejection in solid organ transplantation.","volume":"4","author":"Takemoto","year":"2004","journal-title":"Am J Transplant"},{"key":"R4-21-20210129","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cair.2005.10.002","article-title":"Desensitization protocols improving access and outcome in transplantation.","volume":"5","author":"Zachary","year":"2005","journal-title":"Clin Appl Immunol Rev"},{"key":"R5-21-20210129","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1399-3046.2004.00214.x","article-title":"Transplanting patients with a positive donor-specific crossmatch: A single center's perspective.","volume":"8","author":"Montgomery","year":"2004","journal-title":"Pediatr Transplant"},{"key":"R6-21-20210129","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.med.55.091902.104249","article-title":"Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases [review].","volume":"55","author":"Rastetter","year":"2004","journal-title":"Annu Rev Med"},{"key":"R7-21-20210129","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1600-6143.2004.00507.x","article-title":"Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy.","volume":"4","author":"Sonnenday","year":"2004","journal-title":"Am J Transplant"},{"key":"R8-21-20210129","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1600-6143.2004.00364.x","article-title":"Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers.","volume":"4","author":"Warren","year":"2004","journal-title":"Am J Transplant"},{"key":"R9-21-20210129","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1432-2277.2006.00345.x","article-title":"The emerging role of rituximab in organ transplantation.","volume":"19","author":"Becker","year":"2006","journal-title":"Transpl Int"},{"key":"R10-21-20210129","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.tp.0000261113.30757.d1","article-title":"Rituximab therapy for acute humoral rejection after kidney transplantation.","volume":"83","author":"Faguer","year":"2007","journal-title":"Transplantation"},{"key":"R11-21-20210129","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation.","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"key":"R12-21-20210129","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"R13-21-20210129","first-page":"637","article-title":"The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma (NHL) cell lines.","volume":"88","author":"Maloney","year":"1996","journal-title":"Blood"},{"key":"R14-21-20210129","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","article-title":"Biological response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.","volume":"92","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"R15-21-20210129","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/HAB-2004-13301","article-title":"In vivo human B-cell subsets recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody.","volume":"13","author":"Sidner","year":"2004","journal-title":"Hum Antibodies"},{"key":"R16-21-20210129","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/j.1600-6143.2006.01497.x","article-title":"Pharmacodynamics of rituximab in kidney allotransplantation.","volume":"6","author":"Genberg","year":"2006","journal-title":"Am J Transplant"},{"key":"R17-21-20210129","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1600-6143.2006.01632.x","article-title":"The effect of desensitization protocols on human splenic B-cell populations in vivo.","volume":"7","author":"Ramos","year":"2007","journal-title":"Am J Transplant"},{"key":"R18-21-20210129","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/01.tp.0000282786.58754.2b","article-title":"Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.","volume":"84","author":"Steinmetz","year":"2007","journal-title":"Transplantation"},{"key":"R19-21-20210129","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R20-21-20210129","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R21-21-20210129","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.clim.2006.08.009","article-title":"B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny.","volume":"122","author":"Anolik","year":"2007","journal-title":"Clin Immunol"},{"key":"R22-21-20210129","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s12016-007-8015-4","article-title":"B-cell depletion and repopulation in autoimmune diseases.","volume":"34","author":"Pers","year":"2008","journal-title":"Clinic Rev Allerg Immunol"},{"key":"R23-21-20210129","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/01.tp.0000259017.32857.99","article-title":"HLA-specific B cells. I. A method for their detection, quantification, and isolation using HLA tetramers.","volume":"83","author":"Zachary","year":"2007","journal-title":"Transplantation"},{"key":"R24-21-20210129","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/01.tp.0000259019.68244.d7","article-title":"HLA-specific B cells. II. Application to transplantation.","volume":"83","author":"Zachary","year":"2007","journal-title":"Transplantation"},{"key":"R25-21-20210129","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/01.TP.0000112934.12622.2B","article-title":"Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation, Part 1: Safety, pharmacodynamics and pharmacokinetics.","volume":"77","author":"Vieira","year":"2004","journal-title":"Transplantation"},{"key":"R26-21-20210129","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.transproceed.2005.03.148","article-title":"New protocol of immunosuppression for liver transplantation across ABO barrier: The use of rituximab, hepatic arterial infusion, and preservation of spleen.","volume":"37","author":"Yoshizawa","year":"2005","journal-title":"Transplant Proc"},{"key":"R27-21-20210129","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.healun.2004.09.003","article-title":"Treatment of vascular rejection with rituximab in cardiac transplantation.","volume":"24","author":"Garrett","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"R28-21-20210129","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMc055495","article-title":"Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment.","volume":"354","author":"Pescovitz","year":"2006","journal-title":"N Engl J Med"},{"key":"R29-21-20210129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2215\/CJN.01651105","article-title":"Presensitization: The problem and its management.","volume":"1","author":"Jordan","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R30-21-20210129","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy.","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R31-21-20210129","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.exphem.2005.01.005","article-title":"B lymphocyte reconstitution after hematopoietic stem cell transplantation: Functional immaturity and slow recovery of memory CD27+ B cells.","volume":"33","author":"Avanzini","year":"2005","journal-title":"Exp Hematol"},{"key":"R32-21-20210129","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.clim.2007.11.013","article-title":"Transitional B cells in humans: Characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation.","volume":"127","author":"Marie-Cardine","year":"2008","journal-title":"Clin Immunol"},{"key":"R33-21-20210129","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors.","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"R34-21-20210129","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/lt.21092","article-title":"B-cell surface marker analysis for improvement of rituximab prophilaxis in ABO-incompatible adult living donor liver transplantation.","volume":"13","author":"Egawa","year":"2007","journal-title":"Liver Transpl"},{"key":"R35-21-20210129","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.21650","article-title":"Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: Relationships with B cell depletion, circulating antibodies, and clinical relapse.","volume":"54","author":"Cambridge","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R36-21-20210129","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1097\/TP.0b013e3181735723","article-title":"B cell survival in intragraft tertiary lymphoid organs after rituximab therapy.","volume":"85","author":"Thaunat","year":"2008","journal-title":"Transplantation"},{"key":"R37-21-20210129","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: Relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann Rheum Dis"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00007890-200905150-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:36:14Z","timestamp":1618277774000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-200905150-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,15]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e3181a27683","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5,15]]}}}